Background-Ambulatory blood pressure (ABP) is consistently superior to clinic blood pressure (CBP) as a predictor of cardiovascular morbidity and mortality risk. A common perception is that ABP is usually lower than CBP. The relationship of the CBP minus ABP difference to age has not been examined in the United States.
Introduction
The era of 24-hour ambulatory blood pressure monitoring (ABPM) was ushered in with Perloff and Sokolow's seminal 1983 article on the prognostic value of ABP. 1 During the subsequent 30 plus years, ABPM has been assessed in numerous clinical and population cohorts. The most profound and replicable finding from these studies continues to be the superiority of ABP, compared to clinic blood pressure (CBP), as a correlate of target organ damage and a predictor of cardiovascular (CV) morbidity and mortality risk (see systematic reviews, 2, 3 summarized in Siu 4 ). The explanation of this finding remains unclear.
The use of ABPM also led to the identification of white-coat hypertension -where the CBP is elevated but the average awake ABP (aABP) is not elevated -in cohorts of clinic patients. 5 This, in turn, led to interest in the difference between CBP and aABP, often referred to as the "white-coat effect". Data from numerous cohorts of mostly older patients with hypertension or suspected hypertension showed that CBP was consistently greater than aABP, often by more than 10 mmHg, 6, 7 leading to the commonly held perception, as codified in the JNC 7, that " [A] mbulatory BP values are usually lower than clinic readings (Chobanian et al, p 1214, emphasis added)." 8 When the CBP-ABP difference was subsequently examined in population and communitybased samples with a broad age range, all from Europe, Japan, China and South America, a different picture emerged. After excluding individuals with a history of cardiovascular disease (CVD) and those taking an antihypertensive medication, the average CBP for the full sample was consistently lower than the average aABP. Further analyses, [9] [10] [11] [12] broken down by 10-year age cohorts, showed that the CBP-aABP difference was most negative in the youngest cohorts (aABP higher than CBP) and most positive in the oldest cohorts (CBP higher than aABP). This was confirmed in a meta-analysis of 27 studies and a recent analysis of 9550 untreated individuals. 13, 14 However, the relationship between age and the CBP-aABP difference has not been examined in the United States. This paper extends our understanding of the CBP-aABP difference by, 1) examining for the first time data from a large-scale, healthy, community sample in the United States, and 2) extending the search for correlates of this difference to other demographic factors and body mass index.
Methods
The Masked Hypertension Study is a multi-site study conducted at Stony Brook University and Columbia University. Between 2005 and 2012, 1011 employees of these two universities, their medical schools and affiliated hospitals, and a private hedge fund management organization enrolled in the study. The study adhered to the guidelines set forth by the Declaration of Helsinki and was approved by the institutional review boards of Stony Brook University and Columbia University Medical Center.
Inclusion/exclusion criteria
Recruitment was restricted to employees aged 21 and over who worked ≥17.5 hours/week, spoke and read English, had a pre-enrollment screening blood pressure of <160/105 mmHg, and were not taking a blood pressure lowering medication. Individuals with evidence of secondary hypertension, a history of overt CVD (myocardial infarction, stroke, percutaneous transluminal coronary angioplasty), or chronic renal, liver, thyroid, or adrenal disease were ineligible, as were those with cancer not in remission for at least 6 months, active substance abuse or a serious mental health illness. Those taking any cardiovascular medication (other than a statin) and women who were pregnant were also ineligible. Diabetes was not an exclusion criterion.
Protocol
Recruitment took place on a department by department basis within each organization. With the permission and support of the department head, on-site "public health blood pressure screenings" were conducted by study personnel. All employees were invited to have their BP taken (3 readings taken in accordance with the American Heart Association guidelines). During the 2-minute intervals between readings, the study was briefly described, highlighting the findings that ABP can differ substantially from CBP and that ABP is a better predictor than CBP of CV risk. Those with a screening BP (mean of second and third readings) that was <160/105 mmHg who were not taking blood pressure lowering medication and had no history of overt CVD (e.g., myocardial infarction, cardiac/coronary surgery, stroke) were invited to provide their name and contact information for future recruitment. (Blood pressure screenings were not conducted at the hedge fund management firm. Instead, a public presentation about the study was made to all employees and those interested in potentially participating provided contact information. Eligibility was confirmed during the phone screen, and the BP screening criterion was confirmed at the beginning of Visit 1.) Individuals who provided this information were subsequently contacted by phone, at which time the study protocol was described in detail and full eligibility was ascertained. Those who agreed to participate were then scheduled for the first of 5 study visits (see Figure 1 ) and mailed the study's informed consent document to review.
At Visit 1, individuals provided signed informed consent and then had their CBP taken by a trained technician using a mercury column sphygmomanometer (Baum; Copiague, NY) and stethoscope. The technician confirmed that the participant had not smoked, eaten, or had a caffeinated beverage during the prior 30 minutes and then measured the arm circumference of the non-dominant arm. After being seated comfortably for a minimum of 5 minutes, the participant was asked to remain still, feet flat on the floor and back supported, and to not talk while 3 BP readings were taken at 1-2 minute intervals on the non-dominant arm using an appropriate-sized BP cuff. The participant was given an extensive psychosocial questionnaire to complete at home, and asked to return it by Visit 3.
Visit 2 was scheduled for 1 week later (on a different day of the week and time of day), when the same protocol was used to measure CBP. Visit 3 was scheduled another week later and began with CBP being assessed for the third and final time. The participant was then fitted with a 24-hour ABPM (SpaceLabs 90207, Snoqualamie, WA), a waist actigraphy device (Actical, Philips Respironics, Bend, OR) to assess physical activity, a wrist actigraphy device (ActiWatch, Philips Respironics, Bend, OR) to assess sleep onset/offset and sleep duration, and provided a pre-programmed electronic diary (Palm Pilot Tungsten 3) on which they were asked to answer questions after each BP reading regarding their situation, activities, affect and social interactions immediately prior to the reading. Participants wore the equipment for 24 hours, returning it the next day (Visit 4). At this time, they were scheduled for Visit 5.
During Visit 5, a comprehensive medical history, including family history of major disorders, was obtained by interview. Participants were also interviewed about their smoking history, and completed a health activities questionnaire and health-related quality of life questionnaire (SF-36). 15 Height and weight (no shoes, light clothing) and skinfolds were measured. Fasting blood sample was obtained and urinary albumin and creatinine were measured from a complete overnight urine collection (all voids after going to sleep and first morning void after awakening). A 12-lead electrocardiogram was obtained and a research 2D echocardiogram was performed. Visits 1-4 always took place on a workday, and all visits were conducted at either the hospital clinical research center (CRC) or our lab's clinical offices.
Blood pressure measures
The average of the participant's 3 blood pressure readings taken at Visit 1 is comparable to the assessment of CBP in most epidemiological studies. The average of the 9 readings from Visits 1-3 provides a more robust measure of CBP, and is the measure used in most of our analyses. For comparability with prior studies, some results are also presented for the Visit 1 CBP measure.
The ABP monitor was programmed to take readings at 28-minute intervals and participants were told that readings would be taken "every 25-30 minutes". While it is more typical to use 15-, 20-, or 30-minute intervals, 28 minutes was deliberately chosen to ensure that readings were not taken at the same time each hour, thereby reducing participants' ability to anticipate when the next reading would occur. Based on the manufacturer's recommendation, systolic BP readings outside the range of 70 mmHg (60 mmHg during sleep) to 250 mmHg, and diastolic readings outside the range of 40 mmHg (30 mmHg during sleep) to 150 mmHg were treated as errors. Participants completed a device log, recording the times that they went to sleep, woke up, took a nap, and/or removed any of the equipment (e.g., to exercise or shower). The Actiware software (Philips Respironics) was used to analyze the Actiwatch recording and, in conjunction with the self-report times, arrive at a best estimate of sleep onset and awakening. Based on these times, the average awake and average sleep ambulatory BP were computed. Consistent with the International Database on ABPM in relation to Cardiovascular Outcomes (IDACO), 16 a minimum of 10 valid readings was required to compute the average aABP and a minimum of 5 valid sleep readings was required to compute the average sleep (nighttime) ABP. Of the 893 participants who were fitted with an ABPM device, only 5 had fewer than 10 valid awake readings, leaving a final sample size of 888 participants for analysis. They had an average of 44.3 valid readings (SD: ±7.6; range: 10 -60) and 93.1% (±8.0) of attempted BP readings were successful on either the first try or the automatic re-try 2 minutes later; the average number of valid awake readings was 32.1 (±5.0; range 10 -43). Seventy-five participants did not wear the device to bed and another 41 had fewer than 5 valid sleep readings; the remaining 772 participants had an average of 13.5 (±3.1; range 5 -21) valid sleep readings.
Hypertension categories (BP phenotypes)
Those with a systolic CBP ≥140 mmHg and/or diastolic CBP ≥90 mmHg were classified as having clinic-based hypertension; those with systolic CBP <140 mmHg and diastolic CBP <90 mmHg were classified as having non-elevated CBP or normotension. The corresponding systolic/diastolic aABP thresholds used for the diagnosis of ABP-defined hypertension are 135/85 mmHg. 8, 17, 18 Those with elevated CBP and non-elevated aABP were classified as having white-coat hypertension; those with non-elevated CBP and elevated aABP were classified as having masked hypertension; those whose CBP and aABP were either both elevated or both non-elevated were classified, respectively, as having sustained hypertension or sustained normotension.
Statistical Analysis
The CBP-aABP difference, and how it varies in relationship to other factors, cannot be understood without also examining CBP and aABP separately. Accordingly, we describe and compare the distributions of each -CBP, aABP, and the CBP-aABP difference -in the sample as a whole, and by demographic characteristics. T-tests and analysis of variance are used to test for group differences in means; paired t-tests are used to compare CBP and aABP in the same participant for the full sample and within subgroups. Locally weighted scatterplot smoothing (LOESS) with iterative reweighting is used to model the relationship of the BP measures to age and BMI. The prevalence of each blood pressure phenotype (sustained normotension, white-coat hypertension, masked hypertension, and sustained hypertension) is calculated. Finally, a LOESS logistic model summarizing how the probability of an elevated systolic aABP (i.e., ≥135 mmHg) varies in relationship to the systolic CBP is estimated in the subsample of those with non-elevated CBP; the same is done for diastolic BP. Following multiple imputation for missing Visit 5 data using the "fully conditional specification" approach, 19 multivariable regression models predicting the CBPaABP difference in the full sample and logistic regression models predicting elevated aSBP, elevated aDBP, and masked hypertension status in those with non-elevated CBP were estimated. ANCOVA was used to examine differences among BP phenotypes in echo-defined left ventricular mass index (LVMI, calculated according to the standard ASE formula, 20 indexed by estimated body surface error) and overnight urinary albumincreatinine ratio. A 2-tailed p-value of 0.05 is used to judge statistical significance. All analyses were performed using SAS, version 9.4 (SAS Institute Inc, Cary, NC).
Results
Approximately 2600 employees participated in the on-site BP screenings (see Figure 2 ). Of these, 1931 appeared potentially eligible, of whom 89.1% provided contact information. Phone screens were conducted with 1699 individuals (including 54 from the financial organization where BP screenings were not conducted), and 1254 met all eligibility criteria. A total of 1011 individuals (80.6% of those who were eligible) enrolled in the study and completed Visit 1; 904 (89.4%) had CBP assessed on three separate occasions (Visits 1, 2, and 3); 893 wore the ABPM (888 had 10 or more valid awake readings; 773 had 5 or more valid sleep readings); and 842 (83.3%) completed the cardiovascular evaluation (Visit 5).
The sample is middle-aged (mean 45.0 years, SD= 10.4), 59% female, 7.4% Black/AfricanAmerican and 12% Hispanic, with an average BMI of 27.6 (5.3) kg/m 2 . In the medical history interview, 3.6% reported having diabetes (see Table 1 ). Supplemental Table 1 compares the 888 participants with a valid ABPM recording to the 123 who enrolled in the study but withdrew prior to completing the ABPM (n=118) or had fewer than 10 valid awake ABP readings (n=5). While those who withdrew were younger and more likely to be Black and/or Hispanic, there were no differences in sex or CBP.
The mean (SD) of the Visit 1 systolic/diastolic CBP (average of 3 readings) was 116.1/76.0 (12.9/8.9) mmHg, while the mean pooled across all 3 visits (9 readings in total), was 116.0/75.4 (11.6/7.7) mmHg. The mean (SD) of the average awake and average sleep ABPs were 123.0/77.4 (10.3/7.4) mmHg and 106.2/61.9 (10.5/7.7) mmHg, respectively. The histograms shown in Figure 3 illustrate how the entire distribution of aABP is shifted upward, especially for systolic BP (Panel A), relative to that for CBP (mean of 3 visits). Systolic and diastolic aABP were 7.0 (8.0) and 2.0 (6.5) mmHg higher than CBP (both p<0.0001 by paired t-test). Panels C and D show that CBP minus aABP is approximately normally distributed for both systolic and diastolic BP. Supplemental Figure 1 contains Bland-Altman plots for systolic and diastolic BP showing that, a) the CBP-aABP difference is relatively uncorrelated with the average, and b) the variance of the difference is fairly homogeneous across levels of BP. Table 2 summarizes information about the distribution of difference scores. More than one-third of participants had a systolic aABP that exceeded their CBP by at least 10 mmHg, while only 2.5% had a systolic CBP that exceeded their aABP by this much, a ratio of nearly 14:1. For diastolic BP, more than twice as many participants had an aABP that exceeded their CBP by at least 5 mmHg (32.4%) as had a CBP that exceeded their aABP by this amount (14.2%). Supplemental Table 2 provides the correlations among CBP readings at each visit, the 3-visit average, and the mean awake and sleep ABP.
We next examine how CBP, aABP, and the CBP-aABP difference vary by sex, race, ethnicity, and BMI. As expected, males had higher BP (both CBP and aABP) than females, Blacks had higher BP than non-Blacks (though the differences were not statistically significant due to the relatively small number of Black participants), and those who were overweight or obese had higher BP than those with a normal BMI (see Table 3 ). Hispanics tended to have lower systolic BP than non-Hispanics, but the difference was only statistically significant for systolic aABP. While the subgroup differences in CBP were somewhat larger than in aABP, the CBP-aABP difference did not significantly differ by sex, race, or ethnicity; there was, however, a tendency for the diastolic CBP-aABP difference to be more negative (i.e., aABP greater than CBP) for females than males (p=0.051). (Smoking status [never, past, current] was not significantly associated with systolic or diastolic CBP, aABP, or the CBP-aABP difference; results not shown.) In contrast, the CBP-aABP difference varied considerably with BMI. It was most negative for the normal BMI group and smallest for the obese group; the difference in diastolic BP was slightly positive in the obese group.
It is generally recognized that one factor contributing to the finding that ABP is a superior predictor of adverse CV events, compared to CBP, is that many studies only assessed CBP at a single visit. Averaging CBP across multiple visits increases the reliability of the measure by reducing the impact of visit-to-visit variability. This increased reliability is, in turn, expected to result in statistically stronger associations between CBP and other measures (predictors/correlates of CBP, ABP, and outcomes). This expectation is born out in Table 3 , where a comparison of the t-and F-statistics for the two versions of CBP demonstrates that the associations of demographic factors and BMI with CBP were stronger when CBP was measured as the average across 3 visits (9 readings) instead of just 1 visit (3 readings).
Similarly, Supplemental Table 2 shows that the correlations of CBP with aABP and mean sleep ABP were higher for the 3-visit average CBP than for the single visit CBP measures.
LOESS models were used to examine the relationship of CBP, aABP, and the CBP-aABP difference with age and BMI, treated continuously. As shown in Figure 4 (Panel A), the age gradients of systolic aABP and CBP were non-linear, becoming steeper at higher ages. The difference (CBP being lower than aABP) was greatest for those who were young, but the age gradient of CBP was steeper than that of aABP, especially after age 50, resulting in a steadily decreasing difference at older ages. In this study, the systolic CBP-aABP difference was significantly less than zero (i.e., aABP > CBP) for all ages between 21 and 70 years. Panel B contains the corresponding results for diastolic BP. It shows the curvilinear relationships of diastolic CBP and aABP with age, with the gradient being steeper for CBP than aABP after about age 45; the diastolic aABP was significantly higher than diastolic CBP for all ages below 60. LOESS models of the systolic and diastolic CBP-aABP differences in relation to age appear in Supplemental Figure 2 (Panels A and B ). Figure 4 also shows the relationships of CBP and aABP to BMI (Panels C and D). Systolic and diastolic aABP were substantially higher than CBP for BMI levels below 25 kg/m 2 ; the differences in systolic BP diminished at increasing levels of BMI, but remained statistically significant up to about 43 kg/m 2 ; however, the diastolic CBP-aABP difference became positive for BMI values of 32.5 kg/m 2 and above, and this difference was statistically significant for BMI levels above 35 kg/m 2 . Again, the LOESS models for the CBP-aABP difference appear in Supplemental Figure 2 (Panels C and D).
In multivariable regression models, age and BMI continue to be significantly associated with the CBP-aABP difference in both systolic and diastolic BP. After taking the square root of BMI, its relationship to the CBP-aABP is approximately linear for both BP measures. The relationship of age to the CBP-aABP differences in systolic and diastolic BP is significantly different for men and women. Supplemental Table 3 shows estimates for models that include all predictors (full model), and for parsimonious models where non-significant factors (p≥0.10) have been removed. Supplemental Figure 3 portrays the relationship of age to the systolic and diastolic CBP-aABP differences for men and women. As in the bivariate analyses, Black race and smoking status were not associated with the systolic and diastolic CBP-aABP differences; Hispanic ethnicity was marginally associated with the systolic CBPaABP difference (p=0.09, with the difference being 1.35 mmHg less negative for Hispanics) only.
Diagnostic Categories (BP phenotypes)
In this sample of individuals who were free of CVD, did not screen positive for Stage 2 hypertension, and were not taking any blood pressure lowering medication, 5.3% of the sample were hypertensive by CBP (i.e., ≥140/90 mmHg, based on the average of 9 readings across 3 visits), whereas 19.1% were hypertensive by aABP (i.e., ≥135/85 mmHg). The prevalences of sustained normotension, masked hypertension, white-coat hypertension and sustained hypertension were 79.8%, 14.9%, 1.0% and 4.3%, respectively. Although 84.1% had the same diagnosis by aABP as by CBP, the kappa statistic was only 0.29 (95% CI: 0.21 to 0.37) indicating only poor or fair agreement between the two diagnoses. 21, 22 Of particular interest, 132 (15.7%) of the 841 participants who were normotensive based on their CBP had masked hypertension (aABP ≥135/85 mmHg); 9 (19.1%) of the 47 participants who were hypertensive by CBP had white-coat hypertension (aABP <135/85 mmHg). Of those with masked hypertension, 49 had both elevated systolic and elevated diastolic aABP, whereas 55 had only elevated diastolic aABP, and 28 had only elevated systolic aABP. The probability of having masked hypertension is not the same for all individuals with nonelevated clinic BP. Figure 5 presents plots, based on LOESS logistic analyses of the 841 whose systolic and diastolic CBP were both non-elevated, showing the predicted likelihood of an elevated systolic (Panel A) or diastolic (Panel B) aABP for individuals with different values of CBP. It shows, for example, that 10% of those whose average systolic CBP over 3 visits was 120 mmHg were expected to have a systolic aABP ≥135 mmHg; this increased to 34% for those with a systolic CBP of 130 mmHg and exceeded 50% for those with a systolic CBP of 135 mmHg or greater. Similarly, 20% of those whose average diastolic CBP over 3 visits was 80 mmHg were expected to have a diastolic aABP ≥85 mmHg, and this increased to over 50% for those whose diastolic CBP was 87 mmHg or greater. Tables 4 and 5 show the observed probability of having masked hypertension for different combinations of systolic and diastolic CBP, depending on whether CBP is based on a single visit (Table 4) or three visits (Table 5) .
Males with non-elevated clinic BP were more likely than females to have systolic aABP ≥135, diastolic aABP ≥85 mmHg, and masked hypertension (all p<0.0001); Black race, ethnicity, and smoking status were not significantly associated (all p>0.10). BMI was positively associated with systolic aABP ≥135 (p<0.0001), and masked hypertension (p<0.002), but not diastolic aABP ≥85 mmHg (p=0.35). Age was positively associated with systolic aABP ≥135 (p<0.0001), with no difference between males and females; it was positively associated with diastolic aABP ≥85 mmHg and masked hypertension for males (p=0.004 and p<0.0001), but curvilinearly (inverse U-shape) related for females (p=0.02, and p=0.04).
Clinic BP is overwhelmingly the strongest predictor of who will have elevated aABP and masked hypertension. After controlling for the relationship of clinic systolic BP with systolic aABP ≥135, there was a significant sex*age interaction such that age was independently related to elevated systolic aABP for males only (p=0.009); BMI was no longer associated (see Supplemental Table 4 ). After controlling for the relationship of clinic diastolic BP to diastolic aABP ≥85 mmHg, clinic systolic BP (p=0.02) was positively associated and BMI (p=0.002) was negatively associated; there was a significant sex*age interaction (p=0.008) such that with increasing age, women were less likely (p=0.02) and men were marginally more likely (p=0.07) to have elevated diastolic aABP. Both systolic and diastolic CBP were strong predictors of masked hypertension (both p<0.0001). Controlling for these, there was again a significant sex*age interaction (p=0.003) such that with increasing age, women were marginally less likely (p=0.06) and men were substantially more likely (p=0.006) to have masked hypertension (Supplemental Figure 4) .
Associations of BP Phenotypes with Target Organ Damage
The average left ventricular mass index (LVMI) among those with masked hypertension was significantly higher than among sustained normotensives, but significantly lower than those with sustained hypertension (Supplemental Table 5 ). There were no significant differences in log-transformed urinary albumin-creatinine ratio among the BP phenotypes (p=0.64).
Discussion
In this relatively large U.S. sample of employed adults free of CVD, who had a preenrollment screening BP <160/105 mmHg, and were not taking an antihypertensive medication, ABP was not usually lower than CBP. We found that, on average, systolic aABP was 7 mmHg higher than CBP, and diastolic aABP was 2 mmHg higher. Examination of the distribution of the difference between CBP and aABP revealed that aABP exceeded CBP by 10 mmHg or more in nearly 35% of participants and 9% had a comparably large diastolic difference; in contrast, CBP exceeded aABP by this amount in only 2.5% (systolic) and 4.2% (diastolic) of participants. Thus, while the view that ABP is usually lower than clinic BP may well hold for older individuals with elevated CBP, 8 especially those being treated for hypertension and those wearing an ABPM to rule-out white-coat hypertension, it is not true in this sample or, we suspect, in the general U.S. adult population.
This study confirms findings from non-U.S. population/community studies that the CBPaABP difference varies systematically with age. 9, 12 The difference, with aABP being higher than CBP, is most pronounced in young adults and progressively diminishes at older ages. However, unlike most prior studies, where the difference crossed zero and CBP began to exceed aABP somewhere between the age of 50 and 60, this never happened for systolic BP and only happened for diastolic BP in those above the normal retirement age. Importantly, the number of individuals above the age of 65 in our sample was small and, by design, all were employed. Further research is needed to determine whether this pattern would hold in other samples of employed individuals (e.g., in other types of occupations and organizations, or outside the New York metropolitan area) or in a representative sample of employed, nonemployed and retired individuals. The inclusion of ABPM in the U.S. National Health and Nutrition Examination Survey (NHANES) would allow these and other questions to be addressed. This is one of only a handful of studies to compare the BMI gradients for CBP and aABP. The CBP-aABP difference was greatest, with aABP being higher than CBP, for those with low BMI and became progressively smaller at increasing levels of BMI. For systolic BP, there was no level of BMI at which CBP exceeded aABP whereas for diastolic BP, CBP began to exceed aABP at 32.5 kg/m 2 , and became significantly greater at a BMI of about 35 kg/m 2 . The CBP-aABP difference was similar for men vs. women, Blacks vs. non-Blacks, Hispanics vs. non-Hispanics, and cigarette smokers vs. past smokers vs. never smokers.
One plausible explanation for the finding that the age and BMI gradients of aABP are less steep than the corresponding gradients for CBP is that younger individuals and those with lower BMI are more physically active, raising their aABP substantially above their resting BP. In essence, physical activity might be suppressing the associations of aABP with age and BMI. This potential suppressor effect of physical activity on the relationship of ABP to age and BMI is an important topic for future research, which we hope to address in a future analysis of the actigraphy data collected in this study.
Multivariate regression analyses confirmed the independent associations of age and BMI with the systolic and diastolic CBP-aABP difference. They also revealed that the relationship of age to the difference is different for men and women.
Ideally, primary care physicians will find the results presented here useful when evaluating the BP of a patient during a well-care visit/physical exam. The physician's dilemma is that s/he only knows the patient's CBP, but it is the ABP that is most prognostic. Knowing that if the patient is young and/or has a low BMI, his/her ABP is likely to be considerably higher than the CBP could inform the decision of whether to recommend a 24-hour ABPM. On the other hand, if the patient is 60 years old and mildly obese, then the CBP may be relatively unbiased.
Only 5% of our sample met criteria for hypertension based on CBP, whereas 19% had hypertension based on their aABP. Furthermore, only 1% met criteria for white-coat hypertension, while 14.9% met criteria for masked hypertension. While the goal of the U.K.'s 2011 NICE guideline and the recent United States Preventive Services Task Force (USPSTF) recommendation that ABPM be performed in those with elevated clinic BP in order to rule-out white-coat hypertension and reduce unnecessary treatment is laudable and apparently cost-effective, 4, 23 the current study points to the potential utility of ABPM for identifying the sizeable number of individuals with masked hypertension who are normotensive in the clinic setting but have average daytime blood pressures that exceed the threshold for hypertension. Prior research has shown that these individuals have target organ damage and are at risk for future adverse CV events at rates that exceed those with sustained normotension (i.e., non-elevated CBP and non-elevated aABP) and are similar to those with sustained hypertension, [24] [25] [26] [27] and this is supported by recent findings from the U.S. Dallas Heart Study (using home BP monitoring) and Jackson Heart Study. 28, 29 In the present study, the average LVMI of those with masked hypertension exceeded that for sustained normotensives, but was lower than for sustained hypertensives. Although there is a prima facie case for initiating life style changes and/or blood pressure lowering medication in individuals with masked hypertension, there is, in our opinion, an urgent need for randomized clinical trials testing the effect of potential interventions on CV risk in this population.
Individuals with low CBPs are unlikely to have masked hypertension, since this would require a very large difference between CBP and aABP, for aABP to reach the ambulatory hypertension threshold. As the CBP increases, it becomes increasing likely that the aABP will exceed the threshold for hypertension. This pattern probably explains much of the variability in previously published prevalence estimates of masked hypertension. For example, Viera and colleagues reported a prevalence of 43%, but their sample was restricted to individuals who screened positive for pre-hypertension and had a study CBP ≥110/70 mmHg; 30 this excludes those with the lowest probability of having masked hypertension and results in a prevalence estimate that is considerably higher than that of the general population with non-elevated CBP. Again, inclusion of ABPM in the NHANES would yield a definitive estimate of the masked hypertension prevalence in the U.S. general population. Sex (male), age (especially for men), BMI, and systolic and diastolic CBP were each associated with an increased likelihood of having masked hypertension; smoking status, Black race, and ethnicity were not. With the exception of smoking, these findings are consistent with Sheppard et al's recent systematic review (see their Figure 2 , p 622). 31 Controlling for CBP, the risk of having an elevated systolic aABP, elevated diastolic aABP, or masked hypertension, increases with age for men (OR>1.0), but decreases with age for women (OR<1.0). While the association with sex differs by age, men are at greater risk overall than women. There was also an independent association of BMI with the risk of elevated diastolic aABP only; Black race, Hispanic ethnicity, and smoking status were not significant independent predictors.
When we initiated the Masked Hypertension Study, we were concerned that one factor that might contribute to inflated estimates of the prevalence of masked hypertension and whitecoat hypertension (and the superiority of ABP over CBP for predicting outcomes) could be the poor reliability of the CBP measure, even when taken according to American Heart Association guidelines. 32 Readings from a single visit, no matter how carefully taken, cannot adjust for the well-documented visit-to-visit variability in CBP. 33 This is why we assessed CBP at 3 separate visits. Though not a central focus of the present analysis, the information in Table 3 and Supplemental Table 2 illustrates the increased reliability for CBP that results from averaging the 9 BP readings from 3 clinic visits, compared to the more typical 3 readings taken at a single visit. They show that the association of CBP with demographic factors and BMI are more clearly revealed using the average of 3 visits rather than a single visit. Similarly, the correlations of CBP with mean awake ABP and mean sleep ABP are stronger for the 3-visit measure of CBP than for any of the single visit measures of CBP.
The Masked Hypertension Study has several strengths. In the absence of a nationally representative U.S. sample in which ABPM has been performed, this is one of the largest community samples with 24-hr ABPM in the United States. The sample was relatively healthy, with no evidence of overt CVD (myocardial infarction, stroke, congestive heart failure), no use of cardiovascular medications (except statins), and no use of blood pressure lowering agents. As such, this sample includes those individuals that primary care physicians are likely to see for well-patient visits, an occasion at which screening for hypertension is nearly universal. All participants had employer-provided health insurance, and therefore lack of access to care cannot account for the findings. Furthermore, CBP was assessed on 3 separate visits, with 3 research quality readings taken at each visit, and the average of all 9 readings provides a more reliable measure of CBP than readings from a single visit. However, the high quality of the CBP assessments limits the applicability of our findings, indeed those of almost all ABP studies, to the typical primary care setting. As others have repeatedly bemoaned, 34, 35 the assessment of CBP in usual care is often seriously flawed, deviating procedurally from recommended guidelines. The extent to which our results might inform the difference between usual care clinic blood pressures and ABP is not known.
While the present findings contribute to a better understanding of the difference between CBP and aABP in generally healthy individuals, the study is not without limitations. First, the sample is not representative of the general population. Participants were all employed and had employer-provided health insurance. Second, the exclusion of non-employed individuals resulted in relatively few individuals over age 65, the group in which hypertension is most prevalent. While the sample is well suited to examine the CBP-aABP difference for individuals with non-elevated CBP, with only 5% of participants having elevated CBP (≥140/90 mmHg), it is less useful for examining the difference between CBP and ABP in the clinically important population of individuals with elevated CBP. This study is also unable to address the CBP-aABP difference among those taking an antihypertensive medication. The study did not perform home BP (HBP) monitoring, and therefore the findings may not be relevant to the CBP-HBP difference, or the prevalence and correlates of masked hypertension defined by HBP instead of aABP. Third, the exclusion of those with a screening BP ≥160/105 mmHg not taking medication may introduce a slight bias; however, only 25 of the 2591 screened individuals were excluded solely for this reason. The underrepresentation of Blacks in the sample, is unfortunate. It is similarly unfortunate that minority (Black and Hispanic) participants were more likely to withdraw from the study prior to completing the 24-hour ABPM; importantly, attrition was not associated with blood pressure levels at either Visit 1 or Visit 2. Future population level research that includes ABPM -again as in the U.S. National Health and Nutrition Examination Survey (NHANES) -would address these issues. The present findings In contrast to previous large cohort studies of patients with elevated CBP and thus, to a widely held belief of clinicians, ABP is not usually lower than CBP in healthy employed individuals. Furthermore, a substantial number of otherwise healthy individuals have masked hypertension that may warrant treatment, or at least monitoring. Demonstrated CBP-aABP gradients if confirmed in studies with more diverse samples (e.g., NHANES) may provide guidance for primary care physicians as to when a given CBP indicates the need for ABPM to identify masked hypertension.
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Clinical Perspective

What is new? -
Contrary to common wisdom, we find that mean awake ambulatory blood pressure is typically higher than clinic blood pressure in CVD-free employed persons not being treated for hypertension; this difference is observed in males and females, Blacks and non-Blacks, Hispanics and non-Hispanics, and is especially pronounced in younger individuals and those with lower body mass index.
Approximately 16% of those who have non-elevated BP in the clinic setting, averaged over 3 visits, have elevated average awake ambulatory BP, and therefore have masked hypertension.
What are the clinical implications?
Among those individuals without a diagnosis of hypertension who are seen in a primary care setting, perhaps especially for a well-patient visit, physicians should probably be more concerned that the clinic BP underestimates, rather than overestimates, the patient's average daytime BP.
Given the substantial evidence that an elevated average awake blood pressure over the course of the day increases one's risk for a cardiovascular event, regardless of one's blood pressure in the clinic setting, it is likely that many adults, especially those with prehypertension in the clinic, would benefit from completing a 24-hour ambulatory blood pressure monitoring. Distributions of clinic blood pressure, average awake ambulatory blood pressure, and the difference. Panels A and B show overlapping histograms for systolic and diastolic blood pressure, respectively. Panels C and D show the histograms for the clinic minus ambulatory blood pressure difference. LOESS estimates of the likelihood of exceeding the ambulatory blood pressure threshold for hypertension in relationship to clinic blood pressure (mean of 3 visits). Panel A shows systolic blood pressure; Panel B shows diastolic blood pressure. The shaded areas identify the 95% confidence intervals. The analysis is restricted to the 841 participants who have non-elevated clinic blood pressure (systolic <140 mmHg and diastolic <90 mmHg). Mean (95% Confidence Interval) for Clinic BP, Mean Awake ABP, and the Difference (CBP-aABP) for the total sample and for subgroups Table 4 Percentage of individuals with clinic blood pressure <140/90 mmHg who have masked hypertension, by categories of systolic and diastolic clinic blood pressure (mean of 3 readings taken at the first visit) Table 5 Percentage of individuals with clinic blood pressure <140/90 mmHg who have masked hypertension, by categories of systolic and diastolic clinic blood pressure (mean of 9 readings taken over three visits) 
